August 18, 2022 | Issue #14

In this week's newsletter:

📈 Leveraging longevity biotech

👀 An invitation to Spannr's 

first

 event

🌐 Good reads around the web

How to Evaluate Longevity Stocks

Many investors may balk when they hear “biotech” and “investing” in the same sentence...Long clinical lead times, regulation, and incomprehensible scientific jargon make the longevity biotech industry much more difficult to wrap your head around than most investments. But, the smart money is finally starting to see something in aging research and the biotech firms involved.The groundbreaking therapeutics and science behind these companies stand the chance to change biotech and the world of healthcare as we know it. In the process, of course, this gives early investors the opportunity for substantial returns.That said, perhaps it’s time to take a more reasoned look at the securities available today, the risks involved, and the optimal approach for any investor looking to gain exposure. Continue Reading >>

Mark your calendars: Spannr is pleased to announce that we'll be putting on our first-ever event. The details are still being worked out, but here's all that you need to know for now... 

• When? Friday, 7–9PM, October 7, 2022

• Where? San Diego, California

We've already cut the check, and the venue is officially booked. In other words, despite the short notice – it's going down. Join us on a special night to learn more about investment opportunities, cutting-edge science, and some of the new startups set to change the way humanity ages. We're inviting everyone (that's you!) on this list in hopes of bringing together the industry's top entrepreneurs, investors, and scientists pushing the limits on human aging.Please keep an eye out for another email that should be arriving in the coming weeks related to the event.In the meantime, please do us a favor and reply to this email, simply letting us know whether you're interested in joining us. Again, much more details to follow soon...

• A Wonderful Opportunity: Rethinking life’s stages (Stanford University)

• Rise of intravenous nutrition products among professional team sport athletes: reasons to be concerned? (British Journal of Sports Medicine)

• Smartphone video motion analysis detects narrowed neck arteries that may lead to stroke (American Heart Association)

• A Psychedelic Nexus: Veterans, PTSD, and Longevity (Spannr)

• Global Population Is About to Hit 8 Billion—and Some Argue It Is Near Its Peak (WSJ)

📌 Reminder...

Earlier this month, we announced the launch of the Spannr Longevity Stock Index, designed to simplify and clarify the public longevity sector.Our index consists of US-listed, publicly-traded companies that are explicitly focused on aging or aim to extend healthy human lifespans (more details here).That said, now we get the chance to monitor the performance of these longevity stocks on a week-by-week basis. 👇👇

Performance:

Latest Price: $132.277d-Return: -7.97%Market Cap: $11.28b

Key Drivers:

Denali (DNLI): -10.32%Celularity (CELU): -9.09%Geron (GERN): +6.83%